TERN-501 is a selective thyromimetic drug that is being developed for the treatment of non-alcoholic fatty liver disease.[1][2]

TERN-501
Legal status
Legal status
  • Investigational
Identifiers
  • N-[3,5-dichloro-4-(1-methyl-6-oxo-5-propan-2-ylpyridazin-3-yl)oxyphenyl]-5-oxo-4H-1,2,4-oxadiazole-3-carboxamide
PubChem CID
ChEMBL
Chemical and physical data
FormulaC17H15Cl2N5O5
Molar mass440.24 g·mol−1
3D model (JSmol)
  • CC(C)C1=CC(=NN(C1=O)C)OC2=C(C=C(C=C2Cl)NC(=O)C3=NOC(=O)N3)Cl
  • InChI=1S/C17H15Cl2N5O5/c1-7(2)9-6-12(22-24(3)16(9)26)28-13-10(18)4-8(5-11(13)19)20-15(25)14-21-17(27)29-23-14/h4-7H,1-3H3,(H,20,25)(H,21,23,27)
  • Key:WFIWVDVCNWOMQV-UHFFFAOYSA-N

References

edit
  1. ^ Finan, Brian; Parlee, Sebastian D.; Yang, Bin (April 2021). "Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH". Molecular Metabolism. 46: 101153. doi:10.1016/j.molmet.2020.101153. PMC 8085542. PMID 33359400.
  2. ^ Karim, Gres; Bansal, Meena B (2023). "Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis". TouchREVIEWS in Endocrinology. 19 (1): 60–70. doi:10.17925/EE.2023.19.1.60. ISSN 2752-5457. PMC 10258622. PMID 37313239.